AU Patent

AU2012258558A1 — Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Assigned to Biogen MA Inc · Expires 2013-05-02 · 13y expired

What this patent protects

Methods of treating multiple sclerosis in a subject, including: reducing the frequency of relapse, reducing the annualized relapse rate, reducing the risk of disability progression, reducing the number of new or newly enlarging T2 lesions, reducing the number of gadolinium lesion…

USPTO Abstract

Methods of treating multiple sclerosis in a subject, including: reducing the frequency of relapse, reducing the annualized relapse rate, reducing the risk of disability progression, reducing the number of new or newly enlarging T2 lesions, reducing the number of gadolinium lesions; and methods of preserving/increasing myelin content in a subject having multiple sclerosis; by daily administering a composition containing a fumarate, such as dimethyl fumarate or monomethyl fumarate, to the subject.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012258558A1
Jurisdiction
AU
Classification
—
Expires
2013-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Biogen MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.